Pre-Surgical Tirzepatide-Assisted Weight Loss in Overweight and Obese Men With Intermediate Risk Prostate Cancer: A Pilot Feasibility Study

This pilot study is testing whether tirzepatide — a medication commonly used to treat diabetes and obesity — can help overweight or obese men with intermediate-risk prostate cancer lose weight before surgery (radical prostatectomy), and whether this weight loss might affect cancer outcomes. **You may be eligible if...** - You are a man between 30 and 75 years old - You have intermediate-risk prostate cancer (confirmed by biopsy) and are planning to have surgery - You are overweight or obese (BMI 27 or above) or have been diagnosed with type 2 diabetes **You may NOT be eligible if...** - You have high-risk or metastatic prostate cancer - You have recently lost more than 5 kg unintentionally in the past 90 days - You have received prior prostate cancer treatment - You have severe kidney or pancreatic problems, or a family history of a specific thyroid cancer (medullary thyroid carcinoma) - You have had a serious cardiac event (heart attack, stroke) in the past 3 months - You are currently using weight-loss medication or have had bariatric surgery Talk to your doctor to see if this trial is right for you.